MEBGEN™ BRAF 2 Kit Receives MHLW Approval as a Companion Diagnostic for Use with Patients with Thyroid Cancer
Tokyo, Japan – March 25th , 2024 - Medical and Biological Laboratories Co., Ltd. (CEO: Hiroki Ito, “MBL”), a JSR Life Sciences Company, announced that the MEBGEN™ BRAF 2 Kit was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) on February 21, 2024.
The MEBGEN™ BRAF 2 Kit is a companion diagnostic*1 for encorafenib and binimetinib, for which Ono Pharmaceutical Co., Ltd. has submitted an application for partial change in manufacturing and marketing approval, for an additional indication of “the treatment of radically unresectable BRAFV600-mutant*2 thyroid cancer”. By detecting BRAF gene mutations (V600E, V600K, V600D, V600R, and V600M) in DNA extracted from thyroid cancer tissue, the MEBGEN™ BRAF 2 Kit will be used as an aid in identifying thyroid cancer patients eligible for encolafenib and binimetinib combination therapy.
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of the BRAF gene mutations. MBL will continue to pursue national health insurance coverage for the MEBGEN™ BRAF 2 Kit.
Purpose of use: Detection of BRAF gene mutations (V600E, V600K, V600D, V600R and V600M) in DNA extracted from cancer tissue Used as an aid in identifying thyroid cancer patients eligible for encolafenib and binimetinib combination therapy
Companion diagnostics refers to testing a particular drug in advance of treatment to determine whether it will be effective for the patient and whether there is a significant risk of side effects. The test reagents used for companion diagnosis are called ‘companion diagnostics.’
MBL offers services for the development of companion diagnostics. For more information, please visit https://www.mblbio.com/cdx/
BRAF protein is a serine/threonine kinase that is a component of the Ras/Raf/MEK/ERK signaling pathway.
When the BRAF gene mutation results in the production of abnormal BRAF protein, unregulated cell proliferation leads to cancer.
Combination therapy with encorafenib and binimetinib is expected to be a promising therapeutic option for radically unresectable BRAFV600-mutant thyroid cancer, as BRAF V600 mutations are widely observed in thyroid cancer.
Head Quarters: SUMITOMO FUDOSAN SHIBADAIMON NICHOME BLDG. 2-11-8 Shibadaimon, Minato-ku, Tokyo 105-0012 Japan
Contact form: https://www.mblbio.com/e/contact/
MBL was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics and reagents for basic research. MBL has now expanded its business not only to the immunological field but also to the field of genetic diagnosis. In the field of oncology, MBL is contributing to personalized medicine by developing companion diagnostics. For more information, please visit https://www.mblbio.com/cdx/
Contact details
-
Download vCard
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
Notice of Approval for First-Class Marketing License for Medical Devices
With the acquisition of the First-Class Marketing License for Medical Devices, MBL will be able to market highly controlled medical devices, including genetic testing systems using NGS.
Launch of a New Chemiluminescence Immunoassay Analyzer “iStar500”
The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact & integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency ...
MEBGEN™ BRAF 3 Kit Receives MHLW Approval and Insurance Coverage as a Tumor Agnostic Companion Diagnostic
With MHLW approval and insurance coverage, the MEBGEN™ BRAF 3 Kit is expected to support personalized medicine based on its ability to detect the presence or absence of BRAF gene mutations in rare ...
New Antibody Development for Use in Drug Delivery to Motor Nerves
MBL raised and delivered monoclonal antibodies for Jiksak Bioengineering, a startup company with proprietary technologies developed for new therapeutic innovation in motor neuron degenerative disea...